Mylan (MYL) Sued by Shareholder Over EpiPen Payments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Mylan's (MYL) EpiPen Settlement is Credit-Negative Development - Moody's
October 10, 2016 3:26 PM EDTMoody's Investors Service commented that Mylan's (Nasdaq: MYL) settlement with the US Department of Justice and other government agencies to resolve EpiPen's reimbursement classification with the Centers for Medicaid and Medicare Services is a credit negative development. There are no... More
Mylan's (MYL) EpiPen Settlement with DOJ Removes Key Risk Overhang - Fitch
October 10, 2016 2:21 PM EDTMylan's (Nasdaq: MYL) $465 million settlement of claims it had misclassified its EpiPen injector allays the otherwise significant risk of rebate recoup payments to Medicaid agencies related to the recent EpiPen scrutiny, according to Fitch Ratings. The firm remains subject to other government-related investigations, however.
Mylan announced last week a settlement with the federal government to "resolve questions that have been raised about the classification of EpiPen ... for purposes of the Medicaid Drug Rebate Program," according to a Mylan statement. Mylan had been accused of misclassifying EpiPen as a non-innovator multiple-source (or... More
Mylan (MYL): Don't Get Too Excited - RBC
October 10, 2016 7:24 AM EDTRBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of Mylan (NASDAQ: MYL) as the DOJ Epipen settlement removes the immediate overhang but notes that questions will linger on the P&L outlook. On Friday after the close MYL announced a... More
Mylan to pay $465 million over EpiPen Medicaid rebate dispute
October 7, 2016 5:04 PM EDTBy Deena Beasley
(Reuters) - Mylan NV (NASDAQ: MYL) on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, which has come under intense scrutiny after a series of drastic price increases.
Mylan has been lambasted by consumers and lawmakers for raising prices on the lifesaving EpiPen sixfold to over $600 for a package of two in less than a decade, making the devices unaffordable for a growing number of families.
Lawmakers were trying to... More
